Sarepta Therapeutics Inc to Provides Update on SRP-5051 for the Treatment of Duchenne Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : I know in the past when you highlighted these cases that you noted that there were no occurrences or issues with highlighted markers of kidney function and that these levels have remained normal. Is that still the case with this latest update?

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Do you anticipate that following FDA's discussion to implement any sort of screening criteria for the remainder of the trial, such as baseline kidney function? And if so, what's the percentage of patients could even potentially screen out in the real-world setting?

Question: Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst : So you mentioned that the hypomagnesemia correlates with the dose. I'm just wondering if it's correlating with any other baseline characteristics, like maybe age, weight, BMI, ambulatory status, really just wondering if there's any way we could potentially prospectively identify patients who may be more likely to experience it? Louise R. Rodino-Klapac - Sarepta Therapeutics, Inc. - Executive VP, Chief Scientific Officer and Head of Research & Development Jacob, do you want to take that one? Jacob Elkins Yes. No. I mean it's something we're definitely looking at closely. At this point, we don't -- we haven't identified any baseline predictors. But the thing that we're really focused on is sensitivity in the dose escalation phase, where changes in magnesium are likely to be smaller. It's something that we can identify and then have people that are -- [the less the] patients that are more sensitive to this issue would not undergo the dose escalation.